静脉血栓栓塞性疾病的长期存活率:里瓦罗克萨班与华法林 - 倾向性得分匹配研究
Estefan Ramos-Isaza1, Eduardo Tuta-Quintero1, Alirio Bastidas-Goyes2
1Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia.
BMC pharmacology & toxicology
|December 14, 2023
概括
在静脉血栓栓塞 (VTE) 患者中,里瓦罗克萨班与华法林相比,显示出较低的重大出血风险. 两种抗凝血剂在12个月的生存率是相似的.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉血栓栓塞性疾病 (VTE) 涉及静脉中的血块阻塞.
- 在拉丁美洲,关于华法林与里瓦罗克萨班治疗VTE的数据有限,特别是关于存活率,复发率和出血.
- 这项研究解决了在这个人群中了解抗凝剂有效性和安全性的差距.
研究的目的:
- 为了比较用华法林治疗的VTE患者的存活率,疾病复发和出血事件.
- 在拉丁美洲队列中评估抗凝剂治疗的长期结果.
- 为VTE管理提供基于证据的见解.
主要方法:
- 回顾性队列研究,包括肺栓塞和/或深静脉血栓症患者.
- 倾向性得分匹配分析用于控制混变量.
- 卡普兰-梅尔生存分析和Log Rank测试用于统计比较.
主要成果:
- 在匹配人群中,与华法林 (11.0%) 相比,利瓦罗克萨班 (2.9%) 在12个月内严重出血明显减少 (p=0.001).
- 在6个月 (97.1%对97.6%) 或12个月 (94.7%对95.7%) 里瓦罗克萨班和华法林之间没有观察到生存率的显著差异.
- 两组之间没有发现新的血栓栓塞事件发生的显著差异.
结论:
- 里瓦罗克萨班和华法林在12个月的VTE治疗中显示出可比的存活率.
- 与华法林相比,里瓦罗克萨班与大出血风险显著降低有关.
- 这些发现支持利瓦洛克萨班作为一种潜在的更安全的替代品,用于对流血并发症的VTE管理.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355
Relative Risk
177
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
177
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Assumptions of Survival Analysis
134
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
134
Wilcoxon Signed-Ranks Test for Matched Pairs
134
The Wilcoxon signed-rank test for matched pairs evaluates the null hypothesis by combining the ranks of differences with their signs. It essentially tests whether the median of the differences in a population of matched pairs is zero. Since the test incorporates more information than the sign test, it generally yields more trustable conclusions. This test also does not require the data to follow a normal distribution, but two conditions must be met for it to be applicable: (1) the data must...
134


